Skip to content

NAGE NAGE Cash & Equivalents

Cash & Equivalents at other companies

Nature's Sunshine Products logo
Nature's Sunshine ProductsNATR
$87.58M+1.3%
eXoZymes Inc. Common Stock logo
eXoZymes Inc. Common StockEXOZ
$1.44M-83.0%
Lifevantage Corporation logo
Lifevantage CorporationLFVN
$12.48M-44.4%
Biote Corp. logo
Biote Corp.BTMD
$5.32M-87.2%
NuSkin Enterprises logo
NuSkin EnterprisesNUS
$198.65M-2.5%
USANA Health Sciences logo
USANA Health SciencesUSNA
$165.66M-9.2%

Other financials

Income statement

See full
Revenue$31.5M+3.3%
Gross profit$20.0M+3.3%
Operating income$1.6M-67.0%
Net income$6.3M+24.8%
EPS (diluted)$0.07+16.7%

Balance sheet

See full
Total debt$2.6M-26.9%
Total equity$82.3M+48.8%
Total assets$114.3M+40.6%

Cash flow

See full
Operating cash flow-$1.2M-115%

Valuation

See full
Market cap$254.07M-74.9%
Enterprise value$190.09M-79.7%
P/E13.6×-43.5×
P/S-6.8×

Profitability

See full
Gross margin64.3%+1.8pp
Operating margin10%-2.2pp
Net margin14.3%+1.2pp
FCF margin-70.4%

Returns & leverage

See full
Return on equity27.1%-6.4pp
Debt / equity0.0×
Current ratio4.6×+0.9×

Where this comes from

Reported directly by NAGE in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: NAGE’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about NAGE's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NAGE's cash & equivalents?
NAGE (NAGE) reported cash & equivalents of $66.55M in Q1 2026.
How has NAGE's cash & equivalents changed year-over-year?
NAGE's cash & equivalents increased by 19.7% year-over-year, from $55.62M to $66.55M.
What is the long-term trend for NAGE's cash & equivalents?
Over 5 years (2020 to 2025), NAGE's cash & equivalents has grown at a 31.2% compound annual growth rate (CAGR), from $16.7M to $64.79M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.